Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

PAI-1 contributes to homocysteine-induced cellular senescence.

Sun T, Ghosh AK, Eren M, Miyata T, Vaughan DE.

Cell Signal. 2019 Dec;64:109394. doi: 10.1016/j.cellsig.2019.109394. Epub 2019 Aug 28.

PMID:
31472244
2.

Glycine supplementation extends lifespan of male and female mice.

Miller RA, Harrison DE, Astle CM, Bogue MA, Brind J, Fernandez E, Flurkey K, Javors M, Ladiges W, Leeuwenburgh C, Macchiarini F, Nelson J, Ryazanov AG, Snyder J, Stearns TM, Vaughan DE, Strong R.

Aging Cell. 2019 Jun;18(3):e12953. doi: 10.1111/acel.12953. Epub 2019 Mar 27.

3.

Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis.

Rai R, Sun T, Ramirez V, Lux E, Eren M, Vaughan DE, Ghosh AK.

J Cell Mol Med. 2019 Apr;23(4):3026-3031. doi: 10.1111/jcmm.14162. Epub 2019 Feb 1.

4.

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice.

Henkel AS, Khan SS, Olivares S, Miyata T, Vaughan DE.

Hepatol Commun. 2018 Sep 26;2(12):1479-1492. doi: 10.1002/hep4.1259. eCollection 2018 Dec.

5.

A null mutation in SERPINE1 protects against biological aging in humans.

Khan SS, Shah SJ, Klyachko E, Baldridge AS, Eren M, Place AT, Aviv A, Puterman E, Lloyd-Jones DM, Heiman M, Miyata T, Gupta S, Shapiro AD, Vaughan DE.

Sci Adv. 2017 Nov 15;3(11):eaao1617. doi: 10.1126/sciadv.aao1617. eCollection 2017 Nov.

6.

Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan.

Rai R, Ghosh AK, Eren M, Mackie AR, Levine DC, Kim SY, Cedernaes J, Ramirez V, Procissi D, Smith LH, Woodruff TK, Bass J, Vaughan DE.

Cell Rep. 2017 Nov 7;21(6):1471-1480. doi: 10.1016/j.celrep.2017.10.057.

7.

A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis.

Rai R, Verma SK, Kim D, Ramirez V, Lux E, Li C, Sahoo S, Wilsbacher LD, Vaughan DE, Quaggin SE, Ghosh AK.

Epigenetics. 2017;12(11):1004-1013. doi: 10.1080/15592294.2017.1370173. Epub 2017 Dec 6.

8.

PAI-1 is a critical regulator of FGF23 homeostasis.

Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE.

Sci Adv. 2017 Sep 13;3(9):e1603259. doi: 10.1126/sciadv.1603259. eCollection 2017 Sep.

9.

TGF-β-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche.

Yahata T, Ibrahim AA, Muguruma Y, Eren M, Shaffer AM, Watanabe N, Kaneko S, Nakabayashi T, Dan T, Hirayama N, Vaughan DE, Miyata T, Ando K.

Blood. 2017 Nov 23;130(21):2283-2294. doi: 10.1182/blood-2017-02-767384. Epub 2017 Aug 18.

10.

Complete Plasminogen Activator Inhibitor 1 Deficiency.

Heiman M, Gupta S, Khan SS, Vaughan DE, Shapiro AD.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2017 Aug 3.

11.

Fundamental Cardiovascular Research: Returns on Societal Investment: A Scientific Statement From the American Heart Association.

Hill JA, Ardehali R, Clarke KT, Del Zoppo GJ, Eckhardt LL, Griendling KK, Libby P, Roden DM, Sadek HA, Seidman CE, Vaughan DE; American Heart Association Council on Basic Cardiovascular Sciences; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Stroke Council.

Circ Res. 2017 Jul 21;121(3):e2-e8. doi: 10.1161/RES.0000000000000155. Epub 2017 Jun 26. Review.

PMID:
28652256
12.

Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.

Flevaris P, Khan SS, Eren M, Schuldt AJT, Shah SJ, Lee DC, Gupta S, Shapiro AD, Burridge PW, Ghosh AK, Vaughan DE.

Circulation. 2017 Aug 15;136(7):664-679. doi: 10.1161/CIRCULATIONAHA.117.028145. Epub 2017 Jun 6.

13.

Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.

Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1446-1452. doi: 10.1161/ATVBAHA.117.309451. Epub 2017 Jun 1. Review.

14.

Molecular and physiological manifestations and measurement of aging in humans.

Khan SS, Singer BD, Vaughan DE.

Aging Cell. 2017 Aug;16(4):624-633. doi: 10.1111/acel.12601. Epub 2017 May 23. Review.

15.

Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis.

Kim SJ, Cheresh P, Eren M, Jablonski RP, Yeldandi A, Ridge KM, Budinger GRS, Kim DH, Wolf M, Vaughan DE, Kamp DW.

Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L16-L26. doi: 10.1152/ajplung.00063.2017. Epub 2017 Apr 20.

16.

Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2017 Jan;18:41-44. doi: 10.1016/j.scr.2016.12.003. Epub 2016 Dec 9.

17.

Generation of human iPSCs from urine derived cells of a non-affected control subject.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2017 Jan;18:33-36. doi: 10.1016/j.scr.2016.12.008. Epub 2016 Dec 9.

18.

Generation of human iPSCs from urine derived cells of a patient with a novel homozygous PAI-1 mutation.

Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL.

Stem Cell Res. 2016 Nov;17(3):657-660. doi: 10.1016/j.scr.2016.11.010. Epub 2016 Nov 9.

19.

Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy.

Ghosh AK, Rai R, Flevaris P, Vaughan DE.

J Cell Physiol. 2017 Aug;232(8):1941-1956. doi: 10.1002/jcp.25699. Epub 2017 Feb 28. Review.

PMID:
27883184
20.

A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence.

Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE.

Oncotarget. 2016 Nov 8;7(45):72443-72457. doi: 10.18632/oncotarget.12494.

21.

Response to Letter Regarding Article, "MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis".

Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, Vaughan DE.

Circulation. 2016 Jun 14;133(24):e714. doi: 10.1161/CIRCULATIONAHA.116.022627. No abstract available.

PMID:
27297354
22.

ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model.

Archer AM, Saber R, Rose S, Shaffer A, Misharin AV, Tsai F, Haines Iii GK, Dominguez S, Eren M, Vaughan DE, Cuda CM, Perlman H.

J Transl Med. 2016 Jun 10;14(1):170. doi: 10.1186/s12967-016-0912-y.

23.

DNA Damage: A Main Determinant of Vascular Aging.

Bautista-Niño PK, Portilla-Fernandez E, Vaughan DE, Danser AH, Roks AJ.

Int J Mol Sci. 2016 May 18;17(5). pii: E748. doi: 10.3390/ijms17050748. Review.

24.

MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis.

Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, Vaughan DE.

Circulation. 2016 Jan 19;133(3):291-301. doi: 10.1161/CIRCULATIONAHA.115.018174. Epub 2015 Nov 19.

25.

Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population.

White MJ, Kodaman NM, Harder RH, Asselbergs FW, Vaughan DE, Brown NJ, Moore JH, Williams SM.

PLoS One. 2015 Aug 31;10(8):e0136379. doi: 10.1371/journal.pone.0136379. eCollection 2015.

26.

Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.

Pelisch N, Dan T, Ichimura A, Sekiguchi H, Vaughan DE, van Ypersele de Strihou C, Miyata T.

PLoS One. 2015 Apr 27;10(4):e0124510. doi: 10.1371/journal.pone.0124510. eCollection 2015.

27.

Nitric oxide prevents alveolar senescence and emphysema in a mouse model.

Boe AE, Eren M, Morales-Nebreda L, Murphy SB, Budinger GR, Mutlu GM, Miyata T, Vaughan DE.

PLoS One. 2015 Mar 10;10(3):e0116504. doi: 10.1371/journal.pone.0116504. eCollection 2015.

28.

Role of plasminogen activator inhibitor-1 in senescence and aging.

Eren M, Boe AE, Klyachko EA, Vaughan DE.

Semin Thromb Hemost. 2014 Sep;40(6):645-51. doi: 10.1055/s-0034-1387883. Epub 2014 Aug 31. Review.

29.

PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.

Eren M, Boe AE, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GR, Mutlu GM, Miyata T, Vaughan DE.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7090-5. doi: 10.1073/pnas.1321942111. Epub 2014 Apr 28.

30.

Going mobile: enhanced recovery from myocardial infarction via stem cell mobilization and homing for tissue repair.

Losordo DW, Vaughan DE.

J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2873-4. doi: 10.1016/j.jacc.2014.02.571. Epub 2014 Mar 26. No abstract available.

31.

Drug discovery in renal disease--towards a more efficient framework.

Miyata T, Ando T, Hiragi H, Watanabe K, Yamamoto F, Vaughan DE, Kurokawa T, Oshima Y, van Ypersele de Strihou C, Takeuchi M.

Nat Rev Nephrol. 2014 May;10(5):290-6. doi: 10.1038/nrneph.2014.36. Epub 2014 Mar 18. Review.

PMID:
24642801
32.

Consuming a balanced high fat diet for 16 weeks improves body composition, inflammation and vascular function parameters in obese premenopausal women.

Silver HJ, Kang H, Keil CD, Muldowney JA 3rd, Kocalis H, Fazio S, Vaughan DE, Niswender KD.

Metabolism. 2014 Apr;63(4):562-73. doi: 10.1016/j.metabol.2014.01.004. Epub 2014 Jan 17.

33.

Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea.

Bagai K, Muldowney JA 3rd, Song Y, Wang L, Bagai J, Artibee KJ, Vaughan DE, Malow BA.

Sleep. 2014 Feb 1;37(2):359-67. doi: 10.5665/sleep.3414.

34.

Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Agirbasli M, Eren M, Yasar S, Delil K, Goktay F, Oner ET, Vaughan DE.

J Thromb Thrombolysis. 2014 Jul;38(1):50-6. doi: 10.1007/s11239-013-1021-x.

PMID:
24197654
35.

Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Boe AE, Eren M, Murphy SB, Kamide CE, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE.

Circulation. 2013 Nov 19;128(21):2318-24. doi: 10.1161/CIRCULATIONAHA.113.003192. Epub 2013 Oct 3.

36.

Molecular basis of organ fibrosis: potential therapeutic approaches.

Ghosh AK, Quaggin SE, Vaughan DE.

Exp Biol Med (Maywood). 2013 May;238(5):461-81. doi: 10.1177/1535370213489441. Review.

PMID:
23856899
37.

Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction.

Wan E, Yeap XY, Dehn S, Terry R, Novak M, Zhang S, Iwata S, Han X, Homma S, Drosatos K, Lomasney J, Engman DM, Miller SD, Vaughan DE, Morrow JP, Kishore R, Thorp EB.

Circ Res. 2013 Sep 27;113(8):1004-12. doi: 10.1161/CIRCRESAHA.113.301198. Epub 2013 Jul 8.

38.

Global gene expression profiling in PAI-1 knockout murine heart and kidney: molecular basis of cardiac-selective fibrosis.

Ghosh AK, Murphy SB, Kishore R, Vaughan DE.

PLoS One. 2013 May 28;8(5):e63825. doi: 10.1371/journal.pone.0063825. Print 2013.

39.

A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration.

Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):935-42. doi: 10.1161/ATVBAHA.113.301224. Epub 2013 Mar 7.

PMID:
23471233
40.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. 2013 Jan 23;309(4):343. Erratum in: JAMA. 2015 Jul 7;314(1):86.

41.

A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis.

Rose S, Eren M, Murphy S, Zhang H, Thaxton CS, Chowaniec J, Waters EA, Meade TJ, Vaughan DE, Perlman H.

Ann Rheum Dis. 2013 Jan;72(1):89-95. doi: 10.1136/annrheumdis-2012-201431. Epub 2012 Jun 26.

42.

Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study.

Muldowney JA 3rd, Chen Q, Blakemore DL, Vaughan DE.

Angiology. 2012 Aug;63(6):429-34. doi: 10.1177/0003319712436755. Epub 2012 Feb 17.

PMID:
22345157
43.

A plasminogen activator inhibitor-1 inhibitor reduces airway remodeling in a murine model of chronic asthma.

Lee SH, Eren M, Vaughan DE, Schleimer RP, Cho SH.

Am J Respir Cell Mol Biol. 2012 Jun;46(6):842-6. doi: 10.1165/rcmb.2011-0369OC. Epub 2012 Feb 9.

44.

Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT.

Ghosh AK, Nagpal V, Covington JW, Michaels MA, Vaughan DE.

Cell Signal. 2012 May;24(5):1031-6. doi: 10.1016/j.cellsig.2011.12.024. Epub 2012 Jan 5.

45.

Fibrosis: is it a coactivator disease?

Ghosh AK, Vaughan DE.

Front Biosci (Elite Ed). 2012 Jan 1;4:1556-70. Review.

PMID:
22201975
46.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy ResearchNetwork.

JAMA. 2011 Nov 16;306(19):2110-9. doi: 10.1001/jama.2011.1670. Epub 2011 Nov 14.

47.

Endothelial biology in the post-menopausal obese woman.

Meadows JL, Vaughan DE.

Maturitas. 2011 Jun;69(2):120-5. doi: 10.1016/j.maturitas.2011.03.012. Epub 2011 May 6. Review.

48.

PAI-1 in tissue fibrosis.

Ghosh AK, Vaughan DE.

J Cell Physiol. 2012 Feb;227(2):493-507. doi: 10.1002/jcp.22783. Review.

49.

Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production.

Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, Smith LH.

J Hypertens. 2011 Apr;29(4):724-31. doi: 10.1097/HJH.0b013e32834347de.

50.

Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.

Agirbasli M, Eren M, Eren F, Murphy SB, Serdar ZA, Seckin D, Zara T, Cem Mat M, Demirkesen C, Vaughan DE.

J Thromb Thrombolysis. 2011 Jul;32(1):59-63. doi: 10.1007/s11239-011-0556-y.

PMID:
21311952

Supplemental Content

Loading ...
Support Center